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The hepatic iron regulator hormone hepcidin consists, in its mature form, of 25 amino acids, but two other isoforms, hepcidin-20
and hepcidin-22, have been reported, whose biological meaning remains poorly understood. We evaluated hepcidin isoforms in
sera from 57 control and 54 chronic haemodialysis patients using a quantitative proteomic approach based on SELDI-TOF-MS.
Patients had elevated serum levels of both hepcidin-25 and hepcidin-20 as compared to controls (geometric means: 7.52 versus
4.69nM, and 4.06 versus 1.76nM, resp., P<. 05 for both). The clearance eﬀects of a single dialysis session by diﬀerent dialysis
techniques and membranes were also investigated, showing an average reduction by 51.3% ±29.2% for hepcidin-25 and 34.2% ±
28.4% for hepcidin-20 but only minor diﬀerences among the diﬀerent dialysis modalities. Measurement of hepcidin isoforms
through MS-based techniques can be a useful tool for better understanding of their biological role in hemodialysis patients and
other clinical conditions.
1.Introduction
Regulation of iron metabolism is crucial in diﬀerent types of
cells,especiallyinhepatocytes,enterocytes,andmacrophages
[1]. The major player of this regulation has been recognized
in the small peptide hepcidin, that inhibits iron export from
the cell membrane through internalization and degradation
of ferroportin [2]. Hepcidin is a defensin-like peptide
prevalently produced by the liver as an 84-amino acid
precursor, that undergoes sequential proteolytic cleavage to
form the 25-amino acid bioactive hormone (hepcidin-25).
Additional N-terminal cleavage results in the production of
two smaller isoforms, hepcidin-22 and hepcidin-20, whose
physiologicalroleisstillunclear.Hepcidin-22hasbeenfound
only in urine, where it may merely represent a degradation
product. On the other hand, hepcidin-20 is also present in
blood and appears to possess greater antimicrobial activity
than hepcidin-25 [3] but no capability to bind ferroportin
[4]. Moreover, it has been recently indicated as a possible
serum marker for the acute phase of myocardial infarction
[5], but systematic investigations on this isoform in human
diseases are lacking.
Until recently, studies on hepcidin have been limited by
technical diﬃculties in establishing reliable assays in bio-
logical ﬂuids [6]. Proteomic approaches including Surface-
EnhancedLaserDesorption/Ionization Time-Of-FlightMass
Spectrometry (SELDI-TOF MS) are increasingly used for the
evaluation of biomarkers of clinical interest [7, 8]. Indeed,
we and others have contributed to the development and
validation of an accurate assay of hepcidin in serum and
urine by means of SELDI-TOF MS [9–12]. At variance
with traditional immunochemical methods, the SELDI-TOF
MS technique has the potential to evaluate not only the
predominant 25-amino acid form, but also the shorter
isoforms.2 Journal of Biomedicine and Biotechnology
Hepcidinhasbeenrecentlyobjectofintenseinvestigation
as a potential biomarker of iron status in patients with
chronic kidney diseases (CKD) [13]. Indeed, an adequate
iron availability is critical in hemodialysis (HD) patients,
since it appears to inﬂuence the response to recombinant
erythropoietin (EPO), the mainstay of treatment of anemia
in this condition. In HD patients, various factors may
modulate serum hepcidin levels with opposing inﬂuence
(reviewed in [14]). For example, hepcidin may increase
because of reduced glomerular ﬁltration, iron therapy, and
inﬂammation, with interleukin-6 as a well-known stimulus
for its production [13, 15]. On the other hand, hepcidin may
be reduced by hypoxia, iron deﬁciency, and EPO therapy
by itself [11]. Recent studies using diﬀerent hepcidin assays
have established that serum hepcidin-25 levels are generally
increased in HD patients [16–19], but whether or not it
can represent a useful marker to predict resistance to EPO
remains controversial.
Moreover, little is known about the levels of the hepcidin
isoforms in HD patients, as well as about the eﬀect of a single
dialysis session on the clearance of hepcidins from the blood.
The aims of this study were to evaluate serum levels
of hepcidin-25 and hepcidin-20 by quantitative SELDI-TOF
MS [9] in chronic HD patients, their relationship with
markers of iron status and/or inﬂammation, and the eﬀects
of a single dialysis using diﬀerent protocols on the clearance
of hepcidin isoforms.
2.MaterialsandMethods
Fifty-four stable HD patients treated at the Hemodialysis
Service of our hospital (Ospedale Policlinico, Verona, Italy)
during the period June 2008–July 2009 were included in
the study. Patients were on maintenance with intravenous
erythropoiesis-stimulating agents (ESAs) epoetin or dar-
bepoetin and chronically treated with intravenous iron,
which was stopped 10 weeks before the study. All subjects
were dialyzed against standard, not ultrapure, dialysate.
Diﬀerent protocols were used. Thirty-nine patients were
on bicarbonate HD (BHD), 23 with low-ﬂux synthetic
(11 polysulfone, Fresenius, Germany and 12 polyamide,
Gambro, Sweden), and 16 with high-ﬂux membranes (6
cellulose triacetate, Nipro, Japan, 5 each polysulfone, Frese-
nius, Germany, and polymethylmethacrylate, Toray, Japan).
Eleven patients were on acetate-free bioﬁltration (AFB), a
low-volume hemodiaﬁltration technique based on buﬀer-
free dialysate, a biocompatible high-ﬂux AN69 membrane,
and sterile hypertonic bicarbonate infusion in post-dilution
mode (Hospal, France) [20]. Finally 4 patients were on
HFR (double-chamber hemodiaﬁltration with reinfusion of
regenerate ultraﬁltrate), a technique that utilizes convection,
diﬀusion, and adsorption, using a 0.7m2 high permeability
polyphenylene membrane as a convective dialyzer, a 1.70m2
low-ﬂux polyphenylene membrane as a diﬀusive dialyzer,
and a regenerating adsorbent cartridge containing undis-
solvable macroporous-structured styrenic resin as adsorbent
material (Bellco, Italy) [21]. Dialyzers were not reused. In
all patients the length of the dialysis session was set at 240
Table 1: Clinical features and baseline laboratory data.
HD patients Controls
Number of patients 54 57
Gender (Male/Female) 29/25 38/21
Age (years) 67 ± 14 35 ± 15
HFE genotype
wt/wt (n)3 5 —
H63D/wt (n)1 4 —
C282Y/wt (n)2 —
Hemoglobin (g/dL) 11.4 ± 1.0 14.4 ± 1.2
Iron (µg/dL) 45.2 (43.1−60.0) 96.4 (89.1–104.2)
Transferrin Saturation (%) 20.5 ± 8.3 28.9 ± 9.0
Ferritin (ng/mL) 174 (156−258) 90 (47−149)
CRP (mg/dL) 4.7 (5.0−8.9) 0.8 (0.4−1.4)
Interleukin-6 (pg/mL) 6.8 ± 5.8∗ —
∗Reference range in normal subjects = 0.2–3.2pg/mL.
minutes, and the dialysate ﬂow rate at 500mL/min, the
dialysis blood pump ﬂow rate at 300mL/min, and in the
patients on AFB, the 164mM bicarbonate reinfusion ﬂuid
rate was at 2L/h.
Blood samples for laboratory testing were obtained
prior to the ﬁrst-of-the-week hemodialysis sessions. Blood
samples were collected for detection of C-reactive protein
(CRP), ferritin, and interleukin-6 (IL-6) before the dialysis
session. Serum ferritin was measured by routine laboratory
methods, IL-6 by enzyme-linked immunoadsorbent assay
(by Human IL-6 ELISA BMS213/2CE Bender MedSystems
GmbH,Vienna,Austria),andCRPbycommerciallyavailable
a u t o m a t e dP E N I Aa s s a y s( D a d eB e h r i n g ,G e r m a n y ) .
The eﬀect of the dialysis session on serum hepcidin-25
and hepcidin-20 was evaluated in 39 patients (14 on low-ﬂux
BHD, 12 on high-ﬂux BHD, 9 on AFB, and 4 on HFR) by
measuring hepcidins also at the end of the dialysis sessions
and by calculating the reduction ratio (RR) as follows: RR =
(Cpre − Cpost/Cpre) × 100, where Cpre is the concentration
at the start of dialysis and Cpost the concentration at the
end of dialysis. Cpost was corrected for hemoconcentration
due to ultraﬁltration by multiplying the uncorrected Cpost
for a correction factor computed as the ratio predialysis
Hb/postdialysis Hb.
Fifty-seven controls were enrolled among healthy vol-
unteers participating in a phase II trial at the Centre for
Clinical Research of the Azienda Ospedaliera-Universitaria
di Verona, as described previously in detail elsewhere [12].
Brieﬂy, at enrollment they completed a questionnaire with
speciﬁcitemsrelevanttoironmetabolism(i.e.,anyhistoryof
blood donations, previous pregnancy, menstrual losses, etc.)
and were evaluated by laboratory studies including ferritin,
CRP, liver function tests, and creatinine. To be considered as
appropriate “normal controls” for the serum hepcidin assay,
all these parameters were required to be normal.
The main clinical features of the subjects included in the
study are shown in Table 1.
Each patient gave written informed consent. The study
was conducted according to the principles contained inJournal of Biomedicine and Biotechnology 3
the Declaration of Helsinki. The protocol was approved by
the Institutional Review Board of the Azienda Ospedaliera-
Universitaria di Verona.
2.1. Serum Hepcidin-25 and Hepcidin-20 Assay. We used a
protocol based on PBSCIIc mass spectrometer and copper-
loaded immobilized metal-aﬃnity capture ProteinChip
arrays (IMAC30-Cu2+). FiveµL of serum were applied to
an IMAC30- Cu2+ surface that binds hepcidin based on its
aﬃnity to Cu2+ ions. The binding surface was equilibrated
and washed with appropriate buﬀers according to the manu-
facturs’s instrunctions (Bio-rad, Hercules, CA). Subsequent
work-up, SELDI-TOF MS instrumental settings, read-out,
and data analysis are described elsewhere [12], with the
addition that protein chip handling was performed in a
nitrogen atmosphere to prevent methionine oxidation [9].
Brieﬂy, we used synthetic hepcidin-25 (Peptides Interna-
tional,Louisville,KY)forexternalcalibrationandasynthetic
hepcidin analogue (Hepdicin-24, Peptides International,
Louisville, KY) as an internal standard [9]. Spectra were
collected in duplicate for each sample, with or without the
internal standard spiked in at a concentration of 10nM.
Concentrations of both serum hepcidin-25 and hepcidin-20
were expressed as nM and were the results of the following
equations.
(1) Hepcidin 25 concentration: (sample 2789m/z peak
intensity) × 10nM/(hepc24 spiked sample 2673m/z
peak intensity—nonspiked sample 2673m/z peak
intensity).
(2) Hepcidin 20 concentration: (sample 2192m/z peak
intensity) × 10nM/(hepc24 spiked sample 2673m/z
peak intensity—nonspiked sample 2673m/z peak
intensity).
Standard curves of the internal standard were con-
structed by serial dilutions of hepcidin-24 (0–20nM) in
tubes with blank serum to an end volume of 500µL.
These were immediately applied to IMAC-Cu2+ Chips, and
processedaccording toprotocol and measuredby MS.Linear
standard curves were obtained for hepcidin-24 blank serum
(y = 4.90× + 3.97; R2 = 0.994). Based on the measured
background noise in each MS spectrum for serum samples,
the lower limit of detection (LLOD) ranged from 0.55
to 1.55nM. Since this method is based on the level of
hepcidin-25 peak intensity relative to that of hepcidin-24,
we determined hepcidin-24/hepcidin-25 intensity ratios in
blank serum samples spiked with both synthetic compounds
in duplicate of 8 diﬀerent concentrations. As compared to
our original description of the method [9], recent technical
improvements allowed us to increase the mean peak ratios
hepcidin-24/hepcidin-25 from 0.71 to 0.93.
Protocols for identiﬁcation of peaks by immunological
and mass spectrometry approaches have been described in
detail elsewhere [22]. Hepcidin-25 and hepcidin-20 con-
centrations of 0.55nM were arbitrarily assigned to samples
with undetectable serum levels of hepcidin isoforms. The
intra- and inter-assay coeﬃcient of variations of this method
Table 2:Correlationsbetweenserumhepcidin-25levels,inﬂamma-
tion indices, and serum hepcidin-20 in HD patients.
Correlation coeﬃcient P
Ferritin 0.478 .003
IL-6 0.096 .572
CRP 0.016 .910
Hepcidin-20 0.575 <.001
Table 3:Correlationsbetweenserumhepcidin-20levels,inﬂamma-
tion indices, and serum hepcidin-25 in HD patients.
Correlation coeﬃcient P
Ferritin 0.240 .153
IL-6 0.163 .335
CRP 0.093 .505
Hepcdin-25 0.575 <.001
ranged from 6.1 to 7.3 percent, and from 5.7 to 11.7 (mean
7.7) percent, respectively, [9].
2.2. Statistical Analysis. All calculations were performed
using the SPSS 16.0 software (SPSS Inc., Chicago, IL,
USA). As some of the continuous variables of interest,
including serum hepcidin and ferritin, showed a non-
Gaussian distribution, their values were log-transformed
and expressed as geometric means with 95% Conﬁdence
Intervals (CIs). For other variables, results were expressed
also as means ± SD unless otherwise indicated. Correlations
between quantitative variables were calculated by Pearson r
test. Results were considered signiﬁcant when P was <.05
(two tailed).
3. Results
Figure 1 shows the typical spectra obtained for the region
where hepcidin peptides are detectable. The corresponding
peaks of both hepcidin-20 and hepcidin-25 are visible, along
with the peak of the added standard. Concentrations of
hepcidin-20andhepcidin-25werecalculatedforeachpatient
(before and after dialysis, when available) and control. Both
hepcidin-25andhepcidin-20weresigniﬁcantlyhigherinHD
patientsascomparedtocontrols(Figures2and3):geometric
means with 95% conﬁdence intervals were 7.52nM (5.39–
10.48) in HD patients versus 4.69nM (3.79–5.81) in controls
for hepcidin-25, and 4.06nM (3.45–4.77) in HD patients
versus 1.76nM (1.32–2.35) in controls for hepcidin-20, P<
.05 for both.
Of note, hepcidin-20 was undetectable in 22 out of
57 healthy subjects, while it was always detectable in HD
patients.
Tables 2 and 3 show the correlation coeﬃcients of
hepcidin-25 and hepcidin-20 with serum ferritin and mark-
ers of inﬂammation. Hepcidin-25 was positively correlated
with serum ferritin, but not with inﬂammatory markers. On
the other hand, hepcidin-20 was not signiﬁcantly correlated4 Journal of Biomedicine and Biotechnology
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Figure 1: SELDI-TOF MS proﬁle of hepcidin-24-spiked serum samples of hemodialysis patient (a) and control (b). The hepcidin isoforms
hepcidin-20, hepcidin-24 (synthetic analogue, panel (B)), and hepcidin-25 are indicated by arrows.
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Figure 2: Hepcidin-20 in controls and HD patients. Data presented
as geometric mean with 95% conﬁdence interval.
with either ferritin or inﬂammatory markers, but was
correlated positively with serum hepcidin-25.
The eﬀects of a single dialysis session by the diﬀerent
dialysis techniques and membranes on serum hepcidin
isoforms are shown in Figure 4. On average, we observed a
reduction of 51.3%± 29.2% for hepcidin-25, and of 34.2%±
28.4% for hepcidin-20. The hepcidin-25 reduction ratio was
similar by low- and high-ﬂux BHD; removal by BHD was
alsosimilartoAFBandHFR.Ontheotherhand,hepcidin-25
removalbytheAFBwassigniﬁcantlylowerthanbyHFR(P =
.033) (Figure 4(a)). With respect to hepcidin-20 removal, no
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Figure 3: Hepcidin-25 in controls and HD patients. Data presented
as geometric mean with 95% conﬁdence interval.
signiﬁcant diﬀerence was noted using the diﬀerent dialysis
techniques (Figure 4(b)). Of note, there was no diﬀerence
in predialysis serum levels of both isoforms between the
diﬀerent dialysis modalities (Table 4).
4. Discussion
In this study, SELDI-TOF MS was conﬁrmed as a valuable
approach for the quantiﬁcation of hepcidin levels in serum,
not only with respect to the main isoform, hepcidin-25, butJournal of Biomedicine and Biotechnology 5
Table 4: Predialysis serum hepcidin-25 and hepcidin-20 levels and the diﬀerent HD techniques.
Low-ﬂux BHD (n = 23) High-ﬂux BHD (n = 16) AFB (n = 11) HFR (n = 4)
Hepcidin-25 (nM) 8.0 (7.7–16.2) 7.4 (6.3–16.0) 7.4 (6.0–22.9) 5.7 (0–19.5)
Hepcidin-20 (nM) 4.4 (3.7–6.8) 3.8 (3.1–5.9) 4.2 (2.9–7.4) 2.7 (1.3–4.3)
Data are presented as geometric mean (95% Conﬁdence Interval).
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Figure 4: Reduction Ratio (%) of serum hepcidin-25 (a) and hepcidin-20 (b) by the diﬀerent hemodialysis techniques. (∗Statistically
signiﬁcant P<. 05).
also to hepcidin-20. According to recent data obtained with
various methodological approaches, including competitive
ELISA [19], radioimmunoassay [17], micro-HPLC-tandem-
MS [18], as well as this method [18], hepcidin-25 was
proven to be increased in HD patients as compared to
control subjects. Two studies [17, 19] also observed a
gradual increase of hepcidin-25 across the spectrum of
predialysis CKD, suggesting that diminished renal clearance
is likely the main cause of elevated serum hepcidin-25 in
these pathological conditions. The positive correlation with
serum ferritin, conﬁrmed in this study, indicates that the
physiological regulation of hepcidin-25 by iron stores is
maintained in CKD, though at an upper level as compared
to controls subjects. Besides these conﬁrmatory results,
this study focused on two relatively unexplored aspects of
hepcidinpathophysiologyinHD,forexample,theevaluation
of serum levels of hepcidin-20 and the eﬀects of diﬀerent
dialysis procedures on blood levels of hepcidin isoforms.
4.1. Baseline Serum Hepcidin-20 Levels in HD Patients. We
evaluated for the ﬁrst time serum hepcidin-20 levels in both
normal subjects and HD patients. On average, hepcidin-
20 was signiﬁcantly higher in HD patients as compared to
controls. More precisely, hepcidin-20 was undetectable in
a substantial fraction (near 38%) of healthy subjects but
was always detectable in HD patients. While hepcidin-20
was signiﬁcantly and positively correlated with hepcidin-
25, it was not correlated with either serum ferritin or
markers of inﬂammation, such as CRP and IL-6. No obvious
pathophysiological role of hepcidin-20 can be inferred by
these results. The lack of correlation with iron stores and/or
inﬂammation, for example, the classical stimuli for the
iron bioactive hepcidin-25 isoform, argues against a role
of hepcidin-20 in these conditions. For example, if we
had noted a positive relationship with CRP and/or IL-6,
one could speculate about a selective, inﬂammatory-driven,
posttranslational modiﬁcation of hepcidin to increase the
relative fraction of the isoform with the highest reminiscent
antimicrobial activity. Rather, our results may indicate two
contributing mechanisms as responsible of the increased
hepcidin-20 levels in HD: an altered proteolytic processing
and/or a reduced renal excretion of a catabolic product
normally produced in small amount and nearly completely
eliminated. Inlinewiththisinterpretation isthepositive cor-
relation we observed between hepcidin-20 and hepcidin-25,
suggesting a “tracking eﬀect” of the main isoform. While the
pathophysiological role of hepcidin-20 in HD, if any exists,
remains to be elucidated, the signiﬁcant increase we noted is
not without practical relevance. Indeed, as pointed out in a
recent review [23], while diﬀerent methods uniformly found6 Journal of Biomedicine and Biotechnology
high hepcidin levels in HD, absolute values varied as much as
10-fold depending on the hepcidin assay used. In particular,
the immunological methods generally reported the highest
levels of “hepcidin-25” as compared to MS-based methods,
including the present SELDI-TOF MS. This may be due to,
at least in part, cross-reaction of antibodies with hepcidin-
20. Since in terms of iron homeostasis hepcidin-25 is the sole
bioactiveform,MS-basedmethodsmaybemoreaccuratefor
clinical investigations, notwithstanding being more complex
than traditional immunological methods.
4.2. Eﬀects of Diﬀerent Dialysis Procedures on Blood Lev-
els of Hepcidin Isoforms. The dialysis session appeared
to signiﬁcantly reduce average hepcidin-25 levels, as also
reported by others using MS-based methods [18], but
not immunological methods [17]. We also observed that
the extent of the reduction by dialysis showed a high
interindividual variability (see below) [24]. Of note, the lack
of hepcidin-25 reduction after dialysis reported with [17]
an immunological method was based on results in only 6
HD patients, suggesting the large individual variability as
a possible confounder, beyond the eﬀect of the diﬀerent
methodology employed.
All HD techniques evaluated in our study showed a
comparable removal of hepcidin-25 by dialysis, suggesting
that the removal of this molecule is largely due to diﬀusion.
The most striking result of our study is indeed the large
individual variability of the reduction ratio in patients
treated by the same dialysis modality (ranging from 0 to
95%),suggestingthatpostdialysislevelsmaybeinﬂuencedby
factors other than removal by dialysis. One such factor may
beanincreasedproductionofhepcidin-25duringthedialysis
procedure, which is known to activate an inﬂammatory
response due to the interaction of blood with the dialysis
membranes and/or with a less-than-sterile dialysis ﬂuid
[25]. This possibility is supported by the ﬁnding that the
greatest removal was observed by HFR, a dialysis technique
associated with more eﬃcient removal of cytokines and
reduced levels of markers of inﬂammation (such as CRP
and IL-6) when compared to standard hemodialysis [21].
Alternatively, the improved reduction ratio by HFR may
be due to adsorption, which may provide an important
additional modality for hepcidin-25 removal by dialysis. In
addition, mean predialysis serum hepcidin-25 levels were
lower in patients on long-term HFR (although this diﬀer-
ence was not statistically signiﬁcant), again suggesting that
dialysis modalities with lower activation of the inﬂammatory
response may contribute to reduce the hepcidin-25 burden.
In our study, removal of hepcidin-25 by BHD with
low- and high-ﬂux membranes was similar, at variance with
what reported by Weiss and coworkers [18], who showed
that postdialysis hepcidin-25 levels were lower with high-
ﬂux than low-ﬂux BHD, suggesting an improved removal
by high-ﬂux membranes. These ﬁndings, however, may
not be necessarily conﬂicting, since the eﬀects of dialysis
were evaluated diﬀerently in the two studies. Weiss and
coworkers reported average postdialysis serum levels, while
we computed the reduction ratio by dialysis. In addition,
the diﬀerences between the two studies may be explained by
the large intraindividual variability of the eﬀect of dialysis
reported by both and their small sample size.
Although the removal of hepcidin-20 by the diﬀerent
dialysis modalities was slightly lower than hepcidin-25, this
diﬀerence was not statistically signiﬁcant, suggesting that the
diﬀerent hemodialysis modalities remove the two isoforms
by the same extent and through common mechanisms.
We are aware that the results of our study on the eﬀect
of the diﬀerent dialysis techniques on circulating levels of
hepcidin-25 and hepcidin-20 are preliminary and should
be considered with caution. Clearly, additional studies with
larger sample size and more adequate design are needed to
fully understand the role of the dialysis procedure on serum
levels of the two hepcidin isoforms.
5. Conclusions
Proteomics can be very useful in molecular medicine
nowadays, as precious tools for biomarker discovery and
quantitation. SELDI-TOF MS proteomic analysis enabled
us to evaluate hepcidin isoforms in sera from HD patients
beforeandafterdialysis,givingnewinsightsintothecomplex
pathophysiology of hepcidin in chronic kidney disease.
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